Avalo Therapeutics (NASDAQ:AVTX) Given Buy Rating at BTIG Research

Avalo Therapeutics (NASDAQ:AVTX)‘s stock had its “buy” rating reiterated by stock analysts at BTIG Research in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $58.00 target price on the stock. BTIG Research’s price objective points to a potential upside of 304.75% from the stock’s previous close.

Several other research analysts have also recently weighed in on AVTX. Piper Sandler restated an “overweight” rating and issued a $60.00 price objective (up from $48.00) on shares of Avalo Therapeutics in a research report on Monday, May 11th. Wedbush decreased their price objective on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a research report on Thursday, May 14th. Citigroup restated an “outperform” rating on shares of Avalo Therapeutics in a research report on Wednesday, May 6th. Mizuho upped their price objective on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings upgraded shares of Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $46.67.

Avalo Therapeutics Stock Down 1.8%

Shares of AVTX opened at $14.33 on Tuesday. The business’s 50-day moving average price is $15.55 and its 200-day moving average price is $16.14. Avalo Therapeutics has a twelve month low of $4.46 and a twelve month high of $24.27. The stock has a market cap of $753.33 million, a PE ratio of -2.62 and a beta of 0.83.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.02. Analysts expect that Avalo Therapeutics will post -2.58 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Avalo Therapeutics news, insider Paul Varki sold 75,063 shares of Avalo Therapeutics stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the transaction, the insider directly owned 3,634 shares of the company’s stock, valued at approximately $73,297.78. This trade represents a 95.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 3,970 shares of Avalo Therapeutics stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $18.01, for a total transaction of $71,499.70. Following the transaction, the insider directly owned 3,622 shares in the company, valued at $65,232.22. This trade represents a 52.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 112,586 shares of company stock valued at $2,089,651. 4.46% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Avalo Therapeutics

A number of large investors have recently bought and sold shares of AVTX. PFS Partners LLC boosted its stake in shares of Avalo Therapeutics by 100.0% during the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after purchasing an additional 1,000 shares during the period. BIT Capital GmbH purchased a new stake in shares of Avalo Therapeutics during the third quarter valued at approximately $25,000. Geode Capital Management LLC boosted its stake in shares of Avalo Therapeutics by 2.5% during the second quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock valued at $552,000 after purchasing an additional 2,648 shares during the period. Glenmede Trust Co. NA boosted its stake in shares of Avalo Therapeutics by 25.8% during the first quarter. Glenmede Trust Co. NA now owns 25,730 shares of the company’s stock valued at $384,000 after purchasing an additional 5,280 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Avalo Therapeutics during the third quarter valued at approximately $143,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.